Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.
Launched by UNIVERSITY HOSPITAL, GHENT · Sep 5, 2019
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
Patients will be included after signing informed consent. After inclusion, patients will continue on standard dosing schedule of secukinumab (i.e. subcutaneous injections once a week for 5 weeks (300 mg) followed by subcutaneous injections every 4 weeks). During each study visit blood will be taken in order to quantify Ctroughs and/or anti-drug antibodies towards secukinumab. In addition, Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) score will be evaluated by a physician. Patients complete the Dermatology Life Quality Index (DLQI) and European quality ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
- • 2. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
- Exclusion Criteria:
- • 1. Participants who have currently a predominant nonplaque form of psoriasis
- • 2. Participants who are pregnant, nursing or planning a pregnancy
- • 3. Participants who are unable or unwilling to undergo multiple venapunctures
- • 4. Participants who are treated according to a different dosing schedule than standard dosing of secukinumab
About University Hospital, Ghent
University Hospital Ghent is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. Located in Ghent, Belgium, the hospital is affiliated with Ghent University, fostering a collaborative environment that integrates cutting-edge medical research with high-quality patient care. With a diverse range of specialized departments and a dedicated team of researchers and clinicians, University Hospital Ghent is at the forefront of developing new therapies and improving treatment protocols, aiming to enhance patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Ghent, East Flanders, Belgium
Ghent, Oost Vlaanderen, Belgium
Ghent, Oost Vlaanderen, Belgium
Maldegem, Oost Vlaanderen, Belgium
Torhout, West Vlaanderen, Belgium
Brugge, West Flanders, Belgium
Patients applied
Trial Officials
Jo Lambert, Prof.
Principal Investigator
University Ghent
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials